Vivani Medical (VANI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on December 20. Analyst Naz ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Meanwhile, consumers’ renewed focus on their health and the popularity of GLP-1 weight-loss drugs are showing signs of impacting food manufacturers. GLP-1 users purchase around 8% less food compared ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

Independence Blue Cross joins other insurance companies in restricting coverage of Wegovy and Ozempic to Type 2 diabetes and ...

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...

Jan 2. Highlights: Novo's CagriSema data disappoints, Merck licenses GLP-1 from Hansoh Pharma, and Trump's FTC picks show ...

For an upcoming article, we are looking for stories about what happens to a long-term relationship when one partner decides ...

GLP-1 drugs are remarkably effective at addressing obesity, cardiovascular, and metabolic conditions, but investigators ...

Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a ...

H.C. Wainwright reiterates a Buy rating and $4 price target on Vivani Medical (VANI) shares after the company announced that the first-in-human clinical trial of NPM-115, an exenatide implant based on ...